Definitive Healthcare Corp. (NASDAQ:DH) Given Average Rating of “Reduce” by Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have earned a consensus rating of “Reduce” from the ten analysts that are currently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $3.5214.

Several research analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, January 21st. Barclays dropped their price target on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a research report on Monday, December 8th. Stephens cut their price target on Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Friday, February 27th. Morgan Stanley restated an “underperform” rating and issued a $3.50 price objective on shares of Definitive Healthcare in a research report on Thursday, December 18th. Finally, Canaccord Genuity Group decreased their price objective on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a research note on Friday, February 27th.

Definitive Healthcare Stock Up 5.3%

DH stock opened at $1.19 on Tuesday. The company’s 50 day simple moving average is $1.71 and its 200-day simple moving average is $2.55. The firm has a market capitalization of $124.32 million, a PE ratio of -0.95 and a beta of 1.66. Definitive Healthcare has a 12 month low of $0.97 and a 12 month high of $4.70. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.64 and a quick ratio of 1.64.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds have recently modified their holdings of the company. AQR Capital Management LLC grew its holdings in shares of Definitive Healthcare by 56.7% during the first quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock worth $1,706,000 after buying an additional 213,562 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after buying an additional 7,404,363 shares during the period. Jane Street Group LLC lifted its stake in shares of Definitive Healthcare by 166.0% during the first quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock valued at $304,000 after buying an additional 65,597 shares during the period. Creative Planning boosted its position in Definitive Healthcare by 41.7% during the second quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after acquiring an additional 8,428 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in Definitive Healthcare by 0.4% in the 2nd quarter. New York State Common Retirement Fund now owns 766,433 shares of the company’s stock worth $2,989,000 after acquiring an additional 3,066 shares during the period. 98.67% of the stock is owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.